On Florence Nightingale’s 200th birthday, the legacy of the trailblazing nurse has never been so relevant-as health care workers and researchers across the globe continue to battle against the COVID-19 pandemic.
In an effort to celebrate, honor and connect clinical research workers during this time, Florence Healthcare is calling for nominations of inspiring clinical researcher professionals in an initiative called The Florence Effect. For each nomination, the Florence Effect will make a donation to Greater Gift, and the individual with the most votes will receive a $500 American Express gift card.
Florence hopes this initiative will serve as a platform to appreciate deserving clinical researchers and offer support and encouragement during this challenging time for health care.
You can nominate as many individuals as you’d like, and vote up to 10 times per day.
Get more information here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.